University of Massachusetts Amherst researchers have developed a nanoparticle-based vaccine that they say successfully prevented cancer development in up to 88% of mice during clinical tests.
The vaccine demonstrated remarkable effectiveness against three aggressive cancer types: melanoma, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also prevented the deadly spread of tumors to other organs.
Published in Cell Reports Medicine, the study’s findings represent a unique and promising step toward preventive cancer immunotherapy.
Led by Prabhani Atukorale, assistant professor of biomedical engineering at UMass Amherst, the research team engineered specialized nanoparticles that act as “super adjuvants” to train the immune system to recognize and destroy cancer cells before tumors can establish themselves.
“Our nanoparticles are made from lipids and cholesterol and are very small, on the order of ~50 nanometers in size and spherical in shape. We deliver these nanoparticles alongside peptide or protein antigens that are mixed together like a cocktail in a syringe,” Atukorale recently told The Debrief. “This particular paper focuses on vaccination of healthy mice prophylactically for prevention of tumor development. Upon challenge with tumor cells in multiple cancer models, we found that vaccine-promoted memory prevented tumor growth in a substantial cohort of mice across models.”
The vaccine works by mimicking how natural pathogens trigger robust immune responses. Traditional vaccines often struggle because promising adjuvants—substances that activate immune responses—don’t mix well at the molecular level. Think oil and water. The UMass team solved this problem by creating lipid nanoparticles capable of stably packaging and delivering multiple immune-activating compounds simultaneously.
The researchers conducted two complementary studies to test their vaccine’s effectiveness. In the first trial using well-characterized melanoma antigens, 80% of vaccinated mice remained tumor-free and survived the entire 250-day study period. In stark contrast, all unvaccinated mice and those receiving traditional vaccine formulations developed tumors and died within 35 days.
The second study used a more practical approach, employing killed cancer cells derived directly from tumor masses as vaccine material. This method eliminated the need for complex genetic sequencing to identify specific cancer antigens. Results were striking across all three cancer types: 88% tumor rejection for pancreatic cancer, 75% for breast cancer, and 69% for melanoma.
Perhaps most importantly, the vaccine prevented metastasis—cancer’s spread to distant organs, which accounts for the vast majority of cancer deaths. When researchers exposed vaccinated mice to cancer cells systemically to simulate metastasis, none of the protected animals developed secondary tumors, while all unvaccinated mice did.
The vaccine’s success stems from generating powerful T-cell responses that create lasting “memory immunity” throughout the body.
“There is really intense immune activation when you treat innate immune cells with this formulation, which triggers these cells to present antigens and prime tumor-killing T cells,” said Griffin Kane, the study’s first author and postdoctoral researcher. This immune memory provides systemic protection that traditional treatments cannot match.
“Vaccines have two components,” Atukorale explained. “The tumor antigen (that provides immune recognition of the tumor) and the adjuvant (that provides the costimulatory signaling and cytokines that strengthen the recognition response).”
“Compared to currently approved adjuvants that are mostly given individually in free form (without nanoparticles), our nanoparticle combines two very powerful adjuvants on a single system, thereby conferring ‘super-adjuvant’ attributes,” she added. “This design ensures that both are delivered to the same cell simultaneously. ”
The platform approach means the same nanoparticle system could potentially work against multiple cancer types by simply changing the cancer-specific antigens included. This versatility makes it particularly promising for high-risk individuals, such as those with genetic predispositions or family histories of specific cancers.
Atukorale and Kane have already founded NanoVax Therapeutics to advance this technology toward clinical applications and to further develop their nanoparticle and the treatment approach.
While these results appear remarkably promising, mouse cancer models, despite their utility, often fail to capture the full complexity of human cancers, which develop over decades and involve intricate interactions with aging immune systems, environmental factors, and genetic variations that laboratory mice cannot replicate.
In simple terms, humans often prove to be more complex than the average mouse. While the trials work well on mice, several studies have also been carried out in the past that indicate these trials can often fail to demonstrate similar efficacy in humans.
However, Atukorale says her team’s work is different.
“These gaps in translation are often the case when therapies must be delivered to tumors, which can be intrinsically different between mouse models and human patients,” Atukorale told The Debrief. “In this particular paper, we make the case for prophylactic vaccination, in which we vaccinate healthy mice prior to challenging them with tumor cells.”
“Because a tumor is not present at the time of treatment, which is preventative, we do not expect these same hurdles,” she said.
Although human trials potentially remain several years away, the new research could nonetheless represent a crucial proof-of-concept for cancer prevention immunotherapy.
Going forward, the team plans to extend their work to therapeutic applications for existing cancers, potentially offering prevention and treatment options, both of which will rely on the same underlying technology.
MJ Banias covers space, security, and technology with The Debrief. You can email him at mj@thedebrief.org or follow him on Twitter @mjbanias.